Avadel Other Current Liab from 2010 to 2024

AVDL Stock  USD 15.13  0.12  0.79%   
Avadel Pharmaceuticals Other Current Liabilities yearly trend continues to be quite stable with very little volatility. The value of Other Current Liabilities is projected to decrease to about 15.3 M. From the period between 2010 and 2024, Avadel Pharmaceuticals, Other Current Liabilities regression line of its data series had standard deviation of  21,091,261 and standard deviation of  21,091,261. View All Fundamentals
 
Other Current Liabilities  
First Reported
1996-03-31
Previous Quarter
24.5 M
Current Value
27.9 M
Quarterly Volatility
17.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 10.4 M or Selling General Administrative of 159.3 M, as well as many indicators such as Price To Sales Ratio of 38.26, Dividend Yield of 0.0 or PTB Ratio of 13.55. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.

Latest Avadel Pharmaceuticals' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Avadel Pharmaceuticals PLC over the last few years. It is Avadel Pharmaceuticals' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avadel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Very volatile
   Other Current Liab   
       Timeline  

Avadel Other Current Liab Regression Statistics

Arithmetic Mean20,603,454
Geometric Mean12,507,786
Coefficient Of Variation102.37
Mean Deviation15,760,497
Median14,837,000
Standard Deviation21,091,261
Sample Variance444.8T
Range75.3M
R-Value0.05
Mean Square Error478.1T
R-Squared0
Significance0.87
Slope214,392
Total Sum of Squares6227.8T

Avadel Other Current Liab History

202415.3 M
202324.5 M
20229.3 M
20215.3 M
20205.2 M
20193.9 M
201834.7 M

About Avadel Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Avadel Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Avadel Pharmaceuticals investors use historical funamental indicators, such as Avadel Pharmaceuticals's Other Current Liab, to determine how well the company is positioned to perform in the future. Although Avadel Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Avadel Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Avadel Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Avadel Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Avadel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities24.5 M15.3 M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Avadel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Information and Resources on Investing in Avadel Stock

When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.82)
Revenue Per Share
0.633
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.55)
Return On Equity
(7.80)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.